Legislators And Bond Holders Knocking At Valeant’s Door
This article was originally published in The Pink Sheet Daily
The troubled drug maker received a notice of default from bondholders, while CEO Michael Pearson agreed to be deposed by the Senate’s Special Committee on Aging April 18.
You may also be interested in...
Valeant has begun the search for a new CEO, who will be charged with turning around the troubled company and likely divesting some assets. The company also calls out former CFO Howard Schiller for “improper conduct.”
Members of House Oversight Committee accuse Turing and Valeant of 'trashing' mainstream innovator companies with their drug pricing practices.
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.